Health News

Elan Corporation, plc today announced that findings from a Phase II study which suggested bapineuzumab reduced amyloid-beta deposits in the brains of Alzheimer’s disease patients as measured using a neuroimaging technique known as [11C]PiB PET, were published in the February 28, 2010 online edition of Lancet Neurology. Bapineuzumab is a compound under development by Pfizer and Janssen Alzheimer Immunotherapy, a Johnson & Johnson subsidiary in which Elan holds a minority equity interest.

Read more

Filed under: Pharmacy News
Tags: brain, Online, Pharmacy

Related posts

• Sunitinib shows promise for advanced kidney cancer patients with poor prognosis (0)
  Sunitinib prolongs progression-free and overall survival, and is safe and well tolerated in advanced kidney cancer (metastatic renal cell carcinoma) patients with a poor prognosis such as the elderly and those whose cancer has spread to the brain, finds an Article published Online First (www.thelancet.com) and in the August edition of The Lancet Oncology. Read more [tags] [...]
  
  
• Peregrine Pharmaceuticals’ Cotara specifically targets solid tumors and anti-tumor activity (0)
  Peregrine Pharmaceuticals, Inc. (PPHM) today reported publication of data in the online edition of the journal Current Cancer Therapy Reviews that supports the clinical potential of the company's novel brain cancer agent Cotara® for the treatment of patients with glioblastoma multiforme (GBM), the deadliest form of brain cancer. Cotara specifically targets cells at the center [...]
  
  
• Patients taking warfarin who develop acute stroke more likely to experience brain hemorrhage (0)
  Patients already taking warfarin who develop an acute stroke appear more likely to experience a brain hemorrhage following treatment with an intravenous clot-dissolving medication, even if their blood clotting function appears normal, according to a report posted online today that will appear in the May print issue of Archives of Neurology, one of the JAMA/Archives [...]
  
  
• New Scientific Publication Highlights Long-Term Survival Of Brain Cancer Patients Treated With Peregrine Pharmaceuticals’ Cotara(R) (0)
  Peregrine Pharmaceuticals, Inc. ( PPHM) reported publication of data in the online edition of the journal Current Cancer Therapy Reviews that supports the clinical potential of the company's novel brain cancer agent Cotara® for the treatment of patients with glioblastoma multiforme (GBM), the deadliest form of brain cancer... Read more [tags] Pharmacy News [/tags]
  
  
• Medical Research Community Needs To Speak Louder To Prevent Another Canadian Brain Drain (0)
  Canada may not be able to compete globally in tomorrow's economy, and may repeat the brain drain of the mid-90s as a result of the recent federal budget, states an editorial in CMAJ published online today. Health researchers and clinicians, institutions and others must ensure that the public and government understand the impact of the [...]